Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.

ABSTRACT:

SUBMITTER: Friedman MD 

PROVIDER: S-EPMC5599140 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature